A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) Meeting Abstract
| Authors: | Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P. R.; Dunshee, C.; Ricci, D. S.; Simon, J. S.; Zhao, X.; Kothari, N.; Cheng, S.; Sandhu, S. K. |
| Abstract Title: | A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900010 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.TPS257 |
| Notes: | Meeting Abstract: TPS257 -- Source: Wos |
